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Stephen Hemingway 
 
Abstract 
 
Whilst undertaking the Independent and Supplementary Prescribing Course 
at the University of Sheffield I had the valuable experience of witnessing 
the prescribing of psychotropic medicines for service users’ within a very 
well organised, competent and compassionate intensive home treatment 
team based in Rotherham South Yorkshire. This article is a reflective 
account using a case study that illuminated to me many of the issues 
involved in the decision-making toward the prescribing of drugs. The 
reflection also includes a commentary on some of the issues the 
prescribing nurse must be able work with if they are to competently and 
safely adopt prescriptive authority to their role. 
 
Key words: Nurse Prescribing, Mental Health Nursing, Depression, 
Suicide, Intensive Home Based Treatment 
 
Introduction 
 
This journal will be written in the reflective style of using the first person. 
Webb (1992) alludes to this style of academic writing of realistically 
personalising the writer’s experiences. Thus, my reflections on my 
involvement of the Crisis/Home Treatment Team in the planning, process 
and outcomes of prescribing interventions for the service user used as a 
case study will be analysed in the first person. 
 
Joan is a pseudonym thus protecting her confidentiality as per Nursing and 
Midwifery Council Guidelines (NMC 2004a). The decision to use ‘Joan’s’ 
case history was discussed with my supervising psychiatrist and the team 
as a whole before I undertook the case study.  
 
The structure of the journal will utilise the competency framework outlined 
by the National Prescribing Centre (NPC 2003). Specifically the 
consultation, prescribing effectively and prescribing in context 
competencies will be used to personally critique the structure, process and 
outcome interventions for Joan. 
 
Background 
 
Joan is a 57 year old lady who lives with her husband Anthony in a 
bungalow they intend to be their retirement home. Joan has two sons who 
live long distances from her. Joan had been employed as a doctor’s 
receptionist prior to her present difficulties. Anthony is a self employed 
builder. 
 
Prior to the referral to the Home Treatment Team (HTT), Joan had 
experienced both physically and psychologically adverse events. Whilst at 
a visit to the hairdressers Joan felt a stiffness in her neck and later what 
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she described as a ‘misty eye’. Joan had a consultation with a neurologist. 
Various investigations were undertaken including two MRI scans and blood 
teats. The diagnosis varied between Ischaemic Subclavian Steal Syndrome 
and/or Dorsal Pontine Infarct. Both diagnoses’ related to the area of the 
neck and collar bone Joan had complained of as giving pain and stiffness. 
 
Subsequent to the apparent stroke, Joan became low in mood, lost 
motivation, appetite, lack of sleep and did not find pleasure from life 
whatsoever (anhedonia). All these symptoms were classically symptoms of 
clinical depression described in the DSM IV (Gelder et al 1995). Joan was 
referred privately to a psychiatrist who diagnosed clinical depression and 
prescribed the anti-depressant Mirtazepine with the dose eventually 
reaching 45 milligrams as per normal prescribing limits (BNF 2006). 
Retrospectively Joan’s husband and sons noted improvement in her mood, 
motivation and she had an increased sleep pattern. However the ‘recovery’ 
was short lived. 
 
Earlier in the year Joan intended and actioned plans to commit suicide. 
When her husband had gone to work she took an overdose of mirtazepine 
and paracetamol along with a bottle of wine. Joan had started her car in the 
garage and then lay down on the floor fully intending to end her life. 
Subsequent to this, Joan woke up and rang her husband who alerted the 
emergency services. Joan physically made a full recovery without any 
apparent residual harm. 
 
Joan stopped taking mirtazepine and as Anthony spent some time with 
Joan noted deterioration in mood, motivation, loss of appetite and weight 
and a poor sleep pattern. Joan was seen by her G.P. and was referred to 
the HTT as an alternative to hospital care for assessment of mood and 
mental state and to provide appropriate treatment. A key reason for the 
referral was the risk of suicide. The referral noted Joan’s statements that 
she both personally regretted the fact she had attempted suicide and would 
not want to put her family through such trauma again. However, a relapse 
of symptoms, and past history of a suicide attempt, meant assessment of 
this risk would be ongoing. 
 
Assessment by the Team 
 
Joan and Anthony were initially hostile as they described being let down by 
the services they had consulted (i.e. Neurologist/Surgeon/Osteopath). 
Recent developments also had alienated them from the psychiatric 
services. The consultant neurologist had changed his diagnosis and could 
find nothing totally conclusive regarding a stroke. Secondly, and pertinent 
to the team, a Doctor in the Accident and Emergency Department stated 
that Mirtazepine, the anti-depressant she had been taking, could have had 
a major link to Joan’s suicidal feelings and subsequent action.  
 
Joan and Anthony described her recent mood, mental state and physical 
functioning deteriorating in contrast to the improvement seen before the 
attempt to take her own life. Joan alluded to worries over her neurological 
condition – worrying that she was developing dementia. 
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The Consultation 
 
Discussion regarding Joan’s immediate needs was done at length in the 
team meeting prior to a home visit that would discuss treatment options 
with her and her husband. 
 
Clinical and Pharmaceutical Knowledge/Establishing Options 
 
Prior to the home visit there were immediate issues that needed 
addressing. Firstly, Joan had deteriorated in mood and mental state which 
seemed to be related to the discontinuation of the Mirtazepine. Secondly, 
Joan and her husband were hostile to the idea of anti-depressants due to 
the information they had received at the Accident and Emergency 
department regarding Mirtazepine and possible linkage to the suicidal 
episode. Thirdly, the chance of any post-stroke complications would need 
to be considered. Finally, as the suicide attempt was recent, continuing risk 
assessments would have to be utilised. 
 
The findings of the MRI scans seemed to indicate that Joan had suffered a 
stroke. Post- stroke depression is a common problem and occurs in at least 
30-40% of people suffering a CVA (Gainotti et al 1999). The psychiatrist 
who had seen Joan prior to the suicidal episode had prescribed an 
appropriate drug Mirtazepine, as this drug not only treats depression but 
protects against further depressive episodes post-stroke (Taylor et al 
2005). Recent reports however have shown that the class of drug called 
Selective Re-uptake Inhibitors (SSRI) such as Mirtazepine can cause 
adverse reactions in terms of feelings of agitation/akathisia and active 
suicidal ideation/intention (Healy et al 2005). In interviewing Joan she had 
said that she had a fear of being a burden to her family due to her 
perception that she was developing dementia. It was this worry, rather than 
any particular feeling of agitation, that made her attempt to kill herself. 
Thus, there is no conclusive evidence Mirtazepine, an SSRI, had a causal 
link to the suicidal episode. Added to this, when a person suffering 
depression begins to regain motivation this can also lead to suicidal 
ideation (Stuart and Laraia 2001). 
 
The risk-benefit analysis of which anti-depressant to prescribe for Joan (it 
had been concluded she needed anti-depressant therapy) centred on which 
drug would be most effective for post-stroke depression (Whyte and 
Mulsant 2002), and least likelihood of any adverse event related to suicide 
(Healy and Whitaker 2003). Evidence appeared that Reboxetine a 
Selective Noreadrenaline Re-Uptake Inhibitor is both an effective therapy 
for post-stroke depression (Rampello et al 2005), and, has no causal link to 
suicidal ideation (Tanum 2000). However the HTT had no experience of 
prescribing Reboxetine. Sertraline, an SSRI antidepressant, was 
considered appropriate as it has been used successfully in treating a recent 
case where post-stroke depression had occurred, and, although it has been 
shown to have a causal link with akisthisia induced suicide (Healy and 
Whitaker 2003), the benefits were judged to outweigh the risk element. 
Healy and Whitaker (2003), although critical of the marketing of SSRIs 
regarding the alleged suppression of information in relation to links with 
suicide, do conclude that SSRIs are an effective treatment for depression 
and the risk-benefit conundrum should be taken on an individual basis. 
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In certain types of stroke Warfarin is given post treatment as an anti-
coagulant and this can be enhanced by SSRIs (BNF 2005). However, Joan 
was only prescribed aspirin as an anti-platelet (prophylaxis of 
cardiovascular episodes), and there was no stated interaction between 
sertraline and aspirin (BNF 2006). 
 
Communicating with Patients 
 
The decision to discuss with Joan and her husband about the choice of ant-
depressant was done in the home setting. Dexter and Wash (1997) suggest 
the practitioner needs to be aware of different dynamics of engaging the 
service user in their home setting, where often the control is more with the 
service user and family rather than the clinic or ward context. 
 
There are several models of consultation that can be utilised by the 
prescriber (Baird 2005). However, I believe the model that Stott and Davies 
(1979) described as the most appropriate to analyse interaction between 
Joan and the visiting HTT team members. Stott and Davies (1979) 
identified four areas that can be explored within each consultation: 
management of presenting problem; modification of help seeking 
behaviours review of long term problems; opportunistic health promotion. 
 
Management of Presenting Problems 
 
Engaging the service user and family is key in any consultation (Baird 
2005). Joan and Anthony had recently been disappointed with the way the 
neurologist had communicated the diagnosis with apparent conflicting 
opinions, and, the apparent link with the SSRI prescribed and her suicidal 
episode. Before recommendations were made regarding treatment, an 
opportunity was given for them to ventilate their feelings and relate their 
understanding of their predicament. Joan repeated her disappointment and 
anger over previous contacts with the health service. Anthony was 
particularly assertive in relation to his concerns about SSRIs. Both Joan 
and Anthony agreed her mental state was putting considerable pressure on 
their relationship. 
 
Modification of Behaviour 
 
Consultation with the service user was an opportunity to clarify the position 
the HTT felt was appropriate treatment for Joan and to explain the 
treatment. Firstly, that daily contact was needed to provide support, 
assessment and problem solving interventions. Secondly, that 
antidepressant therapy was necessary and then recommended treatment 
and why. Thirdly, how antidepressants could help Joan’s mood lift and 
subsequently enable her to function more individually and optimally. 
Fourthly, that constant risk assessment regarding Joan’s mental state 
would be undertaken by the team, but this needed to be reciprocal and, if 
low in mood, Joan would need to contact the team as appropriate. 
 
Review of Long Term Problems 
 
Discussion took place about Joan’s long term health needs. Joan had some 
fears that ‘something had happened in my head’ and that this could 
develop into dementia. Acceptance of her fears was made (Dexter and 
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Wash 1997), but reassurance was proffered that although a stroke like 
event was diagnosed, this did not mean she would develop dementia. 
Indeed, if the antidepressant helped to lift her mood the fears regarding the 
worst, dementia, could recede. 
 
Opportunistic Health Promotion 
 
Discussion also took place about how Joan could possibly help herself in 
terms of managing her depressive symptoms and how these interfered with 
her life. A brief explanation about how negative automatic thoughts can 
perpetuate depression was given and how that in certain situations can 
predominate. Therefore, ways of identifying these thoughts and using 
strategies to refocus negative thinking can be an aid to recovery. Joan 
seemed open to re-establishing control of her life but it was agreed that this 
option would be explored as and when her mood lifted and she felt 
motivated to work on her thoughts.  
 
Prescribing Effectively - Safely/Professionally/Improving 
Practice 
 
In discussions regarding the prescribed medication for Joan’s care, I 
witnessed several instances of differences in opinion between psychiatrists 
about what medication to continue or prescribe. Joan for example remained 
fixated on her apparent post-stroke symptoms of stiff neck and ‘not feeling 
right in the head’. The fear that Joan would develop dementia was also 
apparent and something which complicated any outlook by her toward a 
future. Whilst dementia can arise from a stroke and fixed or delusional 
beliefs can be part of the picture post-stroke (Whyte and Mulsant 2002, 
Biran and Chatterjee 2003), how to alleviate her distress/depressive 
predicament and enable her to recover to the optimum was the concern for 
HTT. 
 
Much discussion centred about whether to continue with sertraline and 
increase the dose from 50mg daily as it can be increased to 200mg per day 
(Taylor et al 2005). This could have elevated her mood and resulted in a 
lessened negative ideation regarding her health and future. The opposite 
view was that Joan should have an anti-psychotic medication, Olanzapine, 
prescribed as any attempt to use psychological interventions had not been 
successful. 
 
The discussions over a  period of weeks included the fact that atypical 
antipsychotics have been linked with an increase in cardiovascular events 
(British National Formulary 2006), Joan and Anthony would accept a drug 
usually used for schizophrenia as they had displayed a negative 
attitude/understanding toward mental illness. The risk-benefit discussion 
continued with the decision to start Olanzapine 5mg  as it was considered 
necessary to ‘treat’ elements of  psychotic depression which Joan’s belief 
system appeared to be indicating (i.e. regarding her physical state and 
dementia) The benefit of prescribing Olanzapine to treat the immediacy of 
Joan’s depressive illness was considered high enough to outweigh the 
potential hazard of risk of cardiovascular disease, although her physical 
state would be monitored as per guidelines (British National Formulary 
2006). 
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Reflection 
 
The decision to prescribe Olanzapine was, I feel, undertaken in an 
appropriate mode with time given for anti-depressant therapy and 
psychological interventions to be attempted. The decisions I witnessed in 
the HTT clinical meeting were in the relatively safe confines of a shared 
decision making process where two senior psychiatrists conducted a 
dialogue with the team about Joan’s care and associated prescribing. I 
wondered if I were a supplementary prescriber how I could have 
autonomously made the decision to prescribe for Joan? 
 
Mental Health Nursess have been criticised for lacking the basic knowledge 
of biology and pharmacology to make effective decisions about medication 
(Gournay and Gray 2002, Kingsley et al 2006). Doran (2003) contends that 
prescribing medication for mental health problems is more complex for both 
service user and practitioner than prescribing antibiotics, analgesics, anti-
hypertensives, cardiac and pulmonary medication. The successful 
management of conditions such as depression requires the MHN prescriber 
to resolve a number of complex issues surrounding the choice of treatment 
and expectations of the service user. Lee et al (2006) contend that decision 
making regarding diagnosis and treatment follows a hypothetico-deductive 
model that consists of specific stages. Lee and colleagues (2006) also 
allude to the phenomenological perspective regarding decision making, 
diagnosing and prescribing of intuitive reasoning. Added to this there are 
also some personal, psychological and structural variables. 
 
Prescribing is a complex process, and if acting as a supplementary 
prescribe in the initial development of the Clinical Management Plan 
(CMP),  (a plan of treatment agreed by service user, prescribing nurse and 
supervising psychiatrist), it may have been that as well as an anti-
depressant, use of an antipsychotic would have been added to the CMP. 
However, as described above, the situation with Joan was complicated by 
her apparent negative stance toward mental illness as a concept. If the 
CMP was to be truly agreed between the service user, nurse and 
psychiatrist (NPC 2005) then a frank discussion regarding what was 
included on the CMP would have been necessary. I do not believe at the 
start Joan would have accepted an anti-psychotic with all its negative 
connotations. Therefore, starting with an anti-depressant to treat the 
underlying depressive illness and only then adding the second drug as 
psychotic depression features became more apparent would fit clinical 
need and give time to explain the reasoning behind it. Prescribing and anti-
psychotic medication brings with it the risk of intolerable side effects which 
may then indicate the need for anti-parkinsonian medication such as 
procyclidine (BNF 2006).  
 
To overload the service user with such information with Joan’s depressive 
thoughts, and attitude to mental illness would have negated engagement. 
Thus a staged process, adding medication to the CMP would have been 
necessary. 
 
Regarding prescribing and psychopharmacological knowledge as the 
supplementary prescribed  (SP)  the Nursing Midwifery Council (2006) 
states the nurse needs to act within their own scope of practise. The 
processes described above have shown I would need to be able to have 
sufficient knowledge to be able to consider the appropriate treatment as 
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well take into account psychosocial and service user issues (Lee et al 
2006). Using appropriate channels such as the HTT clinical team meeting, 
as well as the supervising psychiatrist and mental health specialist 
pharmacist would need to be utilised. 
 
In terms of my ability to act as a safe and competent prescriber for Joan I 
feel acting as an SP within the HTT setting with a relative plethora of 
psychiatrists to consult would provide a sound base on which to practice. If, 
however, I were acting in the clinic setting as an Independent Prescriber I 
would question at this stage my ability to be able to act safely and 
competently. Bailey (1999) recommends the novice prescriber start with a 
limited formulary with one class of drug (e.g. anxiolytic, anti-depressant, 
anti-psychotic and anti-manic). Bailey and Hemingway (2006), consider that 
the Supplementary Prescribing route via the CMP is ideal for the nurse to 
build up there confidence before perhaps developing as an Independent 
Prescriber. 
 
As described above there were conflicting opinions of when/if to prescribe 
an anti-psychotic drug for Joan as well as an anti-depressant. Personal 
preference is a factor in prescribing (Courtenay and Griffiths 2005). Two 
Consultant Psychiatrists would have handled the management of 
prescribing medicines for Joan differently. One psychiatrist (my supervisor) 
was more cautious, the other would have been more assertive in the earlier  
use of Olanzapine. I feel the more cautious/staged approach allowed for 
Joan and Anthony to realise an anti-psychotic was necessary. However I 
have been party to interactions with psychiatrists when I have disagreed 
with their prescribing decisions and been overridden. Therefore to disagree 
with the psychiatrist and act autonomously I would need to be confident 
that my decisions were based on knowledge of science and up to date 
facts. 
 
The NHS  in Context 
 
Whilst undertaking the prescribing course it became a possibility to 
prescribe medications independently within my own scope of practice 
(Department of Health 2006). However I will limit my observations to the 
supplementary mode of prescribing as that for me is the way forward as a 
prescriber. The Trust where I have my clinical placement has a policy that 
only allows for mental health nurses to prescribe in a supplementary mode. 
 
Supplementary prescribing was developed with the intention of working 
with chronic illness or in the case of mental health with the long term severe 
and enduring presentations (Davis and Hemingway 2003). This in theory 
would exclude mental health nurses prescribing for clients in the acute 
phases of mental illness (Snowden 2006). However if the supplementary 
prescribing mode is to achieve the aims put forward for non-medical 
prescribing of greater accessibility, choice, flexibility and at the point of 
need (Department of Health 1999), then working as a supplementary 
prescriber within the context of acute mental illness in the home setting is 
no exception to these aims. 
 
I have witnessed both the rigid use of the Clinical Management Plan where 
only three to four medications are prescribed in a memory clinic setting. 
This in practice has resulted in the prescribing nurse making a difference in 
terms of an improved service as well as validating the role of the specialist 
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nurse (Smith and Hemingway 2005, Grant et al 2006). Added to this, I have 
also visited an innovatory mental health nurse in a primary care setting who 
only prescribes a limited amount of controlled drugs. Through the time he is 
able to spend with service users’ who are drug dependent he has also 
made a huge contribution to the improvement in care available especially in 
engaging the person to get some control of their chaotic lives. 
 
The National Prescribing Centre (2005) gives an example of a limited 
clinical management plan where only a limited set and named drug(s) 
prescribed. The NPC (2005) also give an example of a broader clinical 
management plan where the condition is named and that any type of a 
particular drug can be prescribed (for example anti-depressants). As shown 
in the clinical management plan for Joan and debated in the previous 
section of this journal, a broad ranging use of medicines prescribed on the 
plan is necessary. Thus the potential for mistakes to be made by the nurse 
prescriber could be greater. Thus the preparation in terms of policies, 
procedures and administrative tools need to be put into place for the nurse 
to prescribe confidently, competently and safely. Within the HTT there is a 
very supportive framework from the senior medical staff, however it would 
be up to me as an individual to work within trust guidelines, budgetary 
constraints and protocols. 
 
At the time of writing this journal many nurses who have undertaken the 
prescribing course both locally and nationally are not practising prescribers 
after months even years (Latter and Courtenay 2004, Larsen 2005). This 
situation appears to have been created by organisations not keeping up 
with national developments in non-medical prescribing. 
 
My own trust is only finalising the policies and protocols for mental health 
nurses to prescribe supplementarily, and now need to adapt this to the 
possibility of the independent mode. I have witnessed colleagues losing 
confidence and motivation toward developing as a prescriber post-course, 
and I intend to prescribe as soon as possible. The motivation to progress 
my role as a prescriber could otherwise be compromised by the 
bureaucracy of the NHS. 
 
The Team and Individual Context 
 
I was privileged to have such an exceptional and forward thinking 
psychiatrist as my supervisor as well as witnessing the excellent care 
provided by the HTT. The interactions I have observed and taken part in 
during the HTT clinical meetings have shown the team as a whole is well 
informed, as well as service user orientated. 
 
The team sees nurse prescribing as making the service available truly a 24 
hour service rather than the more limited cover psychiatrists can resource. 
Secondary to this, the new working time directive from the European Union 
which will impact in the near future, and the ‘new ways of working’ 
psychiatrists are being encouraged to develop, mean that in reality nurses 
will be resourcing a gap in service. Whether this is seen as ‘dumbing down’ 
of health care (McCartney et al 1999) or truly validating the role that nurses 
have informally undertaken in the past (Ramcharan et al 2001) are 
relatively side issues now. The MHN prescriber will need to be an 
autonomous professional who cannot rely on the umbilical cord every time 
a prescribing decision is made (Fisher and Vaughan-Cole 2003). 
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Allied to a new role being created in the team of the prescribing nurse and 
the impact of this, consideration will need to be given of the changing work 
pattern of the nurse prescriber (Gournay and Gray 2001, NPC 2005).  
 
Within the HTT context, intervention is an alternative to the ward and is 
medical in nature, using psychotropic drugs to relieve symptoms of acute 
mental illness. Within this ‘medical culture’ it could be suggested that the 
nurse would have a relatively smooth transition as much of their 
established role in the team is administering, assessing the therapeutic 
value of medicines or side effects. Prescribing by nurses, however, will 
bring about different relationships with psychiatrists and although I feel the 
supervisory structure is already in situ (ongoing clinical meetings), the 
nurses who have undertaken the prescribing course in the team (four of us) 
need to be more proactive in establishing the role of the prescribing nurse 
within the team. To develop from the underpinnings we are given by the 
prescribing course and supervision with the psychiatrist, undertaking the 
process of prescribing will empower nurses, establish the role in the team, 
and establish it as a new service. 
 
Prescribing has a lot of power elements to it. It is a way of giving a gift to a 
person in distress, it can validate the prescribing professional (up to 
recently the doctor) in terms of role, it can also be seen as medicalising 
care (Walley and Williams 2005). The role of the pharmaceutical industry in 
the prescribing process also needs to be considered. With nurses adopting 
prescriptive authority the potential for them to be targeted by the pharma 
industry is real (Davies and Hemingway 2004). Pharmaceutical companies 
have appointed people who specifically look at the growth potential of non-
medical prescribing. Fears have also been put forward that nurses may be 
ethically compromised if they allow one company to prescribe a drug rather 
than what may be appropriate (Davies and Hemingway 2004). Evidence 
has also shown that doctors are influenced in their prescribing habits by 
interactions with drug companies (Wattana 2000, Moynihan 2003). 
Research in nursing has also shown that prescribing decisions made by 
nurses in the USA have also been influenced by drug companies (Blunt 
2005). Also there is a debate whether we should have any contacts with the 
pharma industry at all (Ashmore and Carver 2001, Hemingway 2003). 
However the reality is that drug companies are a part of the health care 
context in the funding of new drugs and sometimes innovatory practice. 
Some research has even shown information given by pharma 
representatives to be a somewhat valued resource (Talley and Richens 
2001). Blunt (2005) states that interactions with the pharma industry do not 
necessarily need to be demonised, rather the prescribing nurse needs to 
critically use information provided.  They need to be research aware, 
understand what is being presented to them, and be able to critically 
appraise evidence. The NMC (2004b) and ABPI (2006) give guidelines as 
to what is and is not acceptable. The nurse needs to enter any interaction 
with a drug representative with their eyes wide open (Davies and 
Hemingway 2004). 
 
Epilogue 
 
At the time of finishing writing this reflection Joan was on a two week 
holiday with Anthony. Joan has stated some aspects of her life have 
improved, she is sleeping relatively better, at times enjoying life (when she 
forgets she is depressed), renewing some hobbies (i.e. gardening), and is 
S Hemingway 
  129 
 
less preoccupied with the thought she will develop dementia. This is some 
progress, however, she still states she knows something is wrong, and at 
times wonders if she can cope with life as it is now. Medication can only 
help the person cope with a problem and I hope she can get a sense of 
enjoyment and purpose in life as no clinician can create that for an 
individual. 
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